REMATIQ provides an AI-powered platform that streamlines and automates product compliance workflows during medical device development. The platform translates complex regulations such as MDR and FDA into structured, actionable requirements and integrates them into companies' existing systems. REMATIQ aims to speed the path to market for medical devices by simplifying regulatory work and improving safety. The company was founded in 2023 by David Boutellier and Florian Scherer and is headquartered in Berlin, Germany. REMATIQ raised €5.4M in seed funding and plans to use the proceeds to further develop its AI technology, expand its engineering team, and drive international growth across Europe and the United States. No operating metrics were disclosed in the article.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025